The line between a wellness device and a medical one is harder to draw than regulators assume. CFG spoke to founders and experts about the strategic pressures shaping that choice, and what they want policymakers to do about it.
We reviewed more than a hundred wellness neurotechnology company websites — examining their marketing claims, the evidence behind them, and what they do or don't disclose about regulatory status.
Consumer neurotechnologies are outpacing medical ones, raising urgent questions about oversight. Virginia Mahieu argues that Europe must step up to close regulatory gaps and protect mental privacy and democratic values.
Consumer neurotechnology has rapidly expanded beyond medicine into everyday life, prompting CFG’s global analysis of 271 companies to better understand this fast-moving, underexamined sector.
